Navigation Links
Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
Date:10/2/2008

PARSIPPANY, N.J., Oct. 2 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company's management team. David St. Peter, M.D. joins Pacira as Vice President of Medical Education and Scientific Affairs. Dr. St. Peter was previously with inVentiv Health where he held several senior management positions since 2001, most recently serving on their Executive Team as president of The Selva Group, LLC, a medical education and event management company. In addition to industry positions at Marion Merrell Dow and Merck, Sharp & Dohme, he is in private practice and continues to see patients in the acute care setting as a Hospitalist.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

"Dr. St. Peter brings a clear understanding of the critical elements required for successful late-phase market development in the institutional setting. In addition to working closely with our R&D, clinical and commercial teams as we prepare for a successful launch of DepoBupivacaine, we expect his contributions to be broad-based throughout Pacira's overall commercial program," commented chief executive officer Dave Stack.

Dr. St. Peter holds an M.D. from Kansas University Medical Center and a B.S. from the University of Kansas. He completed an internship in surgery at the University of Missouri and St. Lukes Hospital and a residency in medicine at Baptist Medical Center. He is an active member of the AMA, Society of Hospital Medicine, ACRP, APPI, AAFP, Alpha Omega Alpha, Global Alliance for Medical Education (GAME) and the American Medical Writers Association. St. Peter holds active medical licenses in two states and is board certified.

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post-surgical pain. Additional information about Pacira is available at http://www.pacira.com.

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.

Contact: Taunia Markvicka

908-930-4995


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
2. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
3. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
4. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
9. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
10. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
11. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... 26, 2016 , ... BaseHealth , the comprehensive predictive ... as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader with ... recently Chief Commercial Officer of Pathway Genomics. He has held senior executive roles ...
(Date:4/26/2016)... ... , ... This unique "Fertility Happy Hour" event will be held at The ... the lowdown on female fertility and the reproductive technologies that are empowering a new ... IVF - The Arizona Center, will give a short presentation and answer questions ...
(Date:4/26/2016)... , ... April 26, 2016 , ... uBiome, the leading ... new position on the company’s Advisory Board. Prior to co-founding Plum in 2007, Neil ... Senior Designer at IDEO. , A renowned, innovative designer of ideas, products, and brands, ...
(Date:4/26/2016)... ... 2016 , ... Global Stem Cells Group has announced that affiliate ... the keynote speaker at the Asia-Pacific Symposium in Santiago Chile, July 1-2, 2016. The ... regenerative medicine is increasingly being understood to be effected through paracrine factors. Central to ...
Breaking Biology Technology:
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
(Date:3/2/2016)... 2016 http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ... a Service Market 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced ...
Breaking Biology News(10 mins):